Evidence map›Paper›PMID 33849913›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2021

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.

Marie E Wood, Heshan Liu, Elizabeth Storrick, David Zahrieh, H Carisa Le-Petross, Sin-Ho Jung, Patricia Zekan, M Margaret Kemeny, Jayne R Charlamb, Lili X Wang and 5 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Marie E WoodUniversity of Vermont College of Medicine, Burlington, Vermont. Marie.Wood@uvm.edu.
Heshan LiuAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Elizabeth StorrickAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
David ZahriehAlliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
H Carisa Le-PetrossUniversity of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0356-498X
Sin-Ho JungAlliance Statistics and Data Center, Duke University, Durham, North Caroline.
Patricia ZekanSoutheast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Caroline.
M Margaret KemenyQueens Cancer Center, Queens Hospital, Jamaica, New York.
Jayne R CharlambState University of New York Upstate Medical University, Syracuse, New York.ORCID 0000-0002-1019-3219
Lili X WangBay Area Tumor Institute NCORP, Oakland, California.
Gary W UnzeitigDoctor's Hospital of Laredo, Laredo, Texas.
Candace S JohnsonRoswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-1211-4692
Judy E GarberDana-Farber/Partners CancerCare, Boston, Massachusetts.ORCID 0000-0001-9449-3982
James R MarshallRoswell Park Comprehensive Cancer Center, Buffalo, New York.
Isabelle BedrosianUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Mayo Clinic · USRoswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USBay Area Tumor Institute · USDoctors Hospital of Laredo · USDuke University · USMass General Brigham · USQueens Hospital Center · USSoutheast Clinical Oncology Research Consortium · USSUNY Upstate Medical University · USUniversity of Vermont · US

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIESU10CA021076 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KAHL, BRAD · 1985 to 2013
$8.2M
Bay Area Tumor Institute NCORPUG1CA189817 · NCI · BAY AREA TUMOR INSTITUTE · PI BAILEY, LISA (NMN) · 2014 to 2023
$7.7M
OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8M
Lead Academic Participating Site for the Development and Conduct of NCTN TrialsU10CA180798 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MANNEL, ROBERT S., MOORE, KATHLEEN N. · 2014 to 2018
$6.7M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
$6.6M
NCI NIH HHS R21 CA137650NCI NIH HHS U10 CA021060NCI NIH HHS U10 CA021076NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA180790NCI NIH HHS U10 CA180798NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180854NCI NIH HHS U10 CA180857NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180866NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189817NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233191NCI NIH HHS UG1 CA233324
6 · The paper itself

Abstract

Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and toxicity limits use of these agents. Vitamin D is a potential prevention therapy for both ER+ and ER- disease and is safe with few side effects. This study evaluates the effect of 1-year of vitamin D supplementation on mammographic density (MD), a biomarker of breast cancer risk in a multicenter randomized controlled trial. Premenopausal women with ≥25% MD and no history of cancer were randomly assigned to 2,000 international units (IU) of vitamin D or placebo orally daily for 1 year. Change in percent MD was evaluated using Cumulus software after all participants completed treatment. Three hundred women enrolled between January 2011 and December 2013 with a mean age of 43 and diverse ethnicity [14% Hispanic, 12% African American (AA)]. Supplementation significantly increased vitamin D levels compared with placebo (14.5 ng/mL vs. -1.6 ng/mL;

Indexed as

Breast DensityDietary SupplementsAdultBreastBreast NeoplasmsDouble-Blind MethodFemaleHumansMammographyMiddle AgedTreatment OutcomeVitamin DVitamin D

Identifiers

PMID33849913
PMCPMC8449513
OpenAlexW3155810465

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.